Article in Marine drugs, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
10 authors.
Bin LiuInstitute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China. bin0629bin@163.com.
Jiao LiInstitute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China. jiaoli930911@126.com.
Minghua ChenInstitute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China. 15210165499@163.com.
Xiaomeng HaoInstitute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China. xiaomhao@163.com.
Fei CaoKey Laboratory of Medicinal Chemistry and Molecular Diagnostic of Ministry of Education, College of Pharmacy, Hebei University, Baoding 071002, China. caofei542927001@163.com.ORCID 0000-0002-5676-3176
Yi TanInstitute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China. tanyiyi123@126.com.
Yuhui PingCollege of Pharmacy, Jiangxi University of Traditional Chinese Medicine, Nanchang 330004, China. pingyh@163.com.
Yiguang WangInstitute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China. 13552532543@163.com.
Chunling XiaoInstitute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China. xiaocl318@163.com.
Maoluo GanInstitute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China. ganml@imb.pumc.edu.cn.ORCID 0000-0002-3089-8654
Funding
CAMS Innovation Fund for Medical Sciences 2016-I2M-2-002National Natural Science Foundation of China 81872781the Chinese National S&T Special Project on Major New Drug Innovation 2015ZX09304006-016 and 2018ZX09711001-007-002
6 · The paper itself
Abstract
Six new tetracenomycin congeners, saccharothrixones E⁻I (
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Seco-Tetracenomycins from the Marine-Derived Actinomycete · full record | OpenQuestion